尿酸排泄不良型高尿酸血症动物模型 z-bo 2020-12-24 320

　　Purpose: To explore a reliable method for constructing a rat model of dys uric acid excretion of hyperuricemia, and to lay a foundation for the study of the pathogenesis of dys uric acid excretion of hyperuricemia and the optimization of treatment plans.

　　 Method: Use potassium oxazinate (300 mg/kg), pyrazinamide (300 mg/kg), ethambutol (250 mg/kg) to jointly model. The administration was continued for 1 week, 3 weeks, and 5 weeks to detect the levels of uric acid in the blood, urine, and stool of the rats, and to detect liver and kidney functions at the same time, and to observe histopathological sections. Results: The blood uric acid of rats with the combination of potassium oxoxazine and ethambutol increased first and then decreased, while the blood uric acid and urine of the combination of potassium oxoxazine and pyrazinamide were increased during continuous administration. The uric acid in the fluid rises steadily. The two methods have no obvious damage to the liver and kidneys.

　　 Conclusion: The combination of potassium oxazinate and pyrazinamide can effectively establish a rat model of dysuric acid excretion hyperuricemia, and the model has good stability, and its pathogenesis is more in line with the clinical course of uric acid excretion hyperuricemia.